Amifostine

氨磷汀

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameAmifostine
Drug Alias Name氨磷斯丁Gammaphos阿密磷定amifostinum阿米福汀 +[17] 
ClassificationSmall molecules
Mechanisms of ActionAlkaline phosphatase modulators
TargetsAlkaline phosphatase
Therapy Area/IndicationsCytoprotective adjuvantSolid tumoursAcute Radiation Syndrome +[25] 
Global Approved IndicationsCytoprotective adjuvantHead and Neck NeoplasmsOvarian Neoplasms
Approved Indications in ChinaCytoprotective adjuvant
Original Approved Country/TerritoryUnited States
Original Approved Date1995/12/08
Country/TerritoryCanadaUnited StatesPuerto Rico +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesCNX Therapeutics LtdChina Grand Automotive Services Group Co LtdLegacy Pharma Inc
Inactive CompaniesDana-Farber Cancer InstituteWashington University School Of MedicineStanford University +[11] 
Active IndicationsCytoprotective adjuvantHead and Neck NeoplasmsOvarian Neoplasms
Inactive IndicationsSolid tumoursAcute Radiation SyndromeNeutropenia +[22] 

Other Information

ATC CodeV03AF05
Related LinksWikipediaDrugBankKEGG